Cerenis Therapeutics Holding SA (CEREN):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Cerenis Therapeutics Holding SA (CEREN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C7995)・商品コード:DATA904C7995
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:34
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥28,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥57,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥86,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Cerenis Therapeutics Holding SA (Cerenis) is a biopharmaceutical company that discovers and develops HDL therapies for the treatment of cardiovascular and metabolic diseases. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as patients with HDL deficiency, and post-ACS patients. It also develops drugs that increase HDL for patients with low number of HDL particles to treat atherosclerosis and related metabolic diseases. Cerenis works in partnership with other research and biotechnology companies for the development of HDL drug delivery products and technologies. The company has presence in France and the US. Cerenis is headquartered in Labege, France.

Cerenis Therapeutics Holding SA (CEREN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cerenis Therapeutics Holding SA, Medical Devices Deals, 2012 to YTD 2018 9
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Cerenis Therapeutics Acquires Assets from Lypro Biosciences 11
Venture Financing 12
Cerenis Therapeutics Raises USD4.1 Million in Venture Financing 12
Partnerships 13
Cerenis Therapeutics Enters into University of North Texas Health Science Center 13
Equity Offering 14
Cerenis Therapeutics to Raise USD1.3 Million in Private Placement of Shares 14
Cerenis Therapeutics Raises USD56.7 Million in IPO 15
Asset Transactions 17
Cerenis Therapeutics Acquires Assets from Lypro Biosciences 17
Cerenis Therapeutics Holding SA – Key Competitors 18
Cerenis Therapeutics Holding SA – Key Employees 19
Cerenis Therapeutics Holding SA – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Recent Developments 21
Financial Announcements 21
Sep 10, 2018: Cerenis Therapeutics announces 2018 half-year results 21
Jul 18, 2018: Cerenis Therapeutics: Cash position and activity update for H1 2018 and key perspectives for the end of 2018 22
Feb 01, 2018: Cerenis Therapeutics: 2017 Annual Results And Update On Tango 23
Jul 20, 2017: Cerenis Therapeutics: Cash Position and Activity Update for H1 2017 25
Apr 20, 2017: Cerenis Therapeutics : Cash position and update on clinical developments for Q1 2017 26
Jan 19, 2017: Cerenis: Clinical progress, cash position and revenue for Q4 2016 27
Corporate Communications 28
Jul 31, 2018: Cerenis Announces the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director 28
May 02, 2018: Seasoned Scientific Experts and Strategic Pharmaceutical Industry Veterans Join Cerenis’ Scientific Advisory Board in Oncology 29
Other Significant Developments 31
Jan 25, 2018: CERENIS Therapeutics: Cash position and activity update for Q4 2017 31
Oct 26, 2017: Cerenis Therapeutics: Cash Position and Activity Update for Q3 2017 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cerenis Therapeutics Holding SA, Deals By Therapy Area, 2012 to YTD 2018 8
Cerenis Therapeutics Holding SA, Medical Devices Deals, 2012 to YTD 2018 9
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cerenis Therapeutics Acquires Assets from Lypro Biosciences 11
Cerenis Therapeutics Raises USD4.1 Million in Venture Financing 12
Cerenis Therapeutics Enters into University of North Texas Health Science Center 13
Cerenis Therapeutics to Raise USD1.3 Million in Private Placement of Shares 14
Cerenis Therapeutics Raises USD56.7 Million in IPO 15
Cerenis Therapeutics Acquires Assets from Lypro Biosciences 17
Cerenis Therapeutics Holding SA, Key Competitors 18
Cerenis Therapeutics Holding SA, Key Employees 19
Cerenis Therapeutics Holding SA, Other Locations 20
Cerenis Therapeutics Holding SA, Subsidiaries 20

List of Figures
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cerenis Therapeutics Holding SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cerenis Therapeutics Holding SA, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[Cerenis Therapeutics Holding SA (CEREN):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C7995)販売に関する免責事項を必ずご確認ください。
★調査レポート[Cerenis Therapeutics Holding SA (CEREN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆